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A B S T R A C T   
The glomerular filtration rate (GFR) is considered the best overall index for the renal function. Currently, one of 
the most promising exogenous markers for GFR assessment is iohexol. In this study, the suitability of volumetric 
absorptive microsampling (VAMS) as alternative for the conventional blood sampling and quantification of 
iohexol in paediatric plasma was assessed. Therefore, a new, fully validated liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) method was developed. Subsequently, the clinical suitability was evaluated in 20 
paediatric patients by comparing plasma iohexol concentrations and associated GFR values obtained by the 
VAMS method with those obtained by conventional blood sampling and quantification of iohexol in plasma. The 
developed, simple and cost-effective LC-MS/MS-method fulfilled all pre-set validation acceptance criteria. 
Iohexol could be accurately quantified within a haematocrit range of 20–60% and long-term stability of iohexol 
in VAMS was demonstrated up to 245 days under different storage temperatures. Both iohexol plasma con-
centrations (r = 0.98, mean bias: − 4.20%) and derived GFR values (r = 0.99; mean bias: 1.31%), obtained by a 
conventional plasma and the VAMS method, demonstrated good correlation and acceptable bias. The agreement 
between the two methods was especially good for GFR values higher than 60 mL/min/1.73 m2. Nevertheless, for 
GFR values <60 mL/min/1.73 m2 the accuracy compared to the plasma method was lower. However, small 
adjustments to the sampling protocol could probably solve this problem.   
1. Introduction 
In divergent physiological and pathological conditions, the assess-
ment of the kidney function is essential to make optimal clinical de-
cisions [1]. Generally, the glomerular filtration rate (GFR) is considered 
the best overall index of kidney function in healthy and diseased people 
[2,3]. The GFR is most frequently estimated based on serum creatinine. 
Nevertheless, the use of serum creatinine has some major drawbacks, 
since serum creatinine levels can be affected by multiple factors, making 
the estimated GFR (eGFR) less accurate [4]. In general, the determina-
tion of the kidney function by use of the eGFR is sufficient, but in some 
cases, such as chronic illness, diagnosis of early kidney disease, drug 
dose adjustment and monitoring the impact or toxicity of certain 
treatments, more accurate measurements of the renal function are 
needed [1,5]. The urinary clearance of inulin is still considered the gold 
standard method for GFR determination [6]. Yet, due to complexity of 
the protocol and high cost, intensive research has been performed to 
propose alternative, exogenous filtration markers that are cheap, easy to 
use and accurate [1]. This resulted in a diversity of filtration markers, 
with each having its own (dis)advantages [6]. 
Iohexol, a contrast agent, is proposed by Delanaye et al. as the best 
suited marker to replace inulin, since its properties approach those of an 
ideal GFR marker [7]. Iohexol is negligibly bound to plasma proteins, 
freely filtered by the kidneys, does not undergo tubular secretion nor 
reabsorption and has a low extra-renal excretion [7–11]. Consequently, 
urine collection is not mandatory. Furthermore, it is virtually non-toxic 
and carries a low cost [7]. Due to its favourable characteristics, iohexol 
is currently the most widely used exogenous marker for GFR measure-
ments in Europe [7,12]. 
There are several liquid chromatography-based methods reported in 
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literature describing the quantification of iohexol in human plasma or 
serum using either ultraviolet or mass spectrometric detection [13–17]. 
Also other assays, including X-ray fluorescence and capillary electro-
phoresis, are available [18–20]. These assays generally require larger 
sample volumes of blood (>200–500 µL) obtained by phlebotomy [21]. 
Consequently, the last decade there has been a keen interest from the 
bioanalytical field in alternative microsampling techniques for quanti-
fication of iohexol [22–26]. These alternative microsampling ap-
proaches are of particular interest for sampling in the paediatric 
population, since they require a smaller sample volume (≤50 µL), and 
are often less painful and stressful. Furthermore, they have generally 
fewer requirements on handling and storage [21,27,28]. 
Currently, dried blood spot (DBS) sampling is the most frequently 
used dried microsampling technique for iohexol quantification [23–26]. 
Notwithstanding the ease of use, a major obstacle of this technique is the 
effect of haematocrit on the assay variability [28,29]. The haematocrit 
value of the blood can affect the resultant size of the spot, which 
consequently can influence the correct quantification of the analyte 
[28]. Luis-Lima et al. encountered possibly such a haematocrit effect 
when employing non-volumetric DBS for iohexol determination, 
resulting in inaccurate and imprecise GFR measurements [26]. To 
overcome the haematocrit-induced biases, the volumetric absorptive 
microsampling (VAMS) technique was designed to reduce the volume 
variation owing to alteration in haematocrit values [30]. Nevertheless, 
haematocrit can still influence the recovery of the analyte and its effect 
should therefore always be checked during validation [30]. Currently, to 
the authors’ knowledge, only a single literature report published by Ion 
et al. is available describing a VAMS assay for iohexol [31]. 
The objective of the current study was to develop and validate an 
ultra-high performance liquid chromatography-mass spectrometry 
(UHPLC-MS/MS) assay for the quantification of iohexol using VAMS 
devices. In contrast to the recent paper published by Ion et al., in this 
paper special attention was paid to the long-term stability of the samples 
and the influence of haematocrit on the method accuracy [31]. 
Furthermore, a pilot study was designed to assess the suitability of this 
VAMS technology as alternative for the conventional quantification of 
iohexol in paediatric plasma. To the authors’ knowledge, this is the first 
study evaluating the correlation and agreement of iohexol plasma con-
centrations and GFR determination obtained with VAMS and a con-
ventional plasma method. 
2. Materials and methods 
2.1. Chemicals, standards and reagents 
The analytical standard of iohexol, trifluoroacetic acid (TFA) and 
perchloric acid were purchased from Sigma-Aldrich (Bornem, Belgium). 
The internal standard (IS), iohexol-d5, was obtained from Alsachim 
(Illkirch-Graffenstaden, France). Ultrapure (UP) water was generated 
with a Milli-Q system (Merck-Millipore, France). Methanol (MeOH) and 
acetonitrile (ACN) were all of ULC-MS grade and were acquired from 
Biosolve (Valkenswaard, the Netherlands). Acetone, trichloroacetic acid 
(TCA) and formic acid (FA) were obtained from VWR International 
(Leuven, Belgium). Ten microliter VAMS devices (brand name Mitra™) 
were purchased from Neoteryx (Torrance, CA, USA). 
For the analytical experiments, a stock solution of iohexol was pre-
pared in UP water at a concentration of 10 mg/mL. This solution was 
prepared in water to minimally change the nature of the blood samples 
when spiking. The stock solution was stored at 2–8 ◦C. A stock solution 
of iohexol-d5 was made in MeOH at a concentration of 1 mg/mL. This 
stock solution was aliquoted and stored at ≤− 15 ◦C. Working solutions 
were prepared by appropriate dilution of the stock solution in water, and 
were stored at 2–8 ◦C. 
2.2. VAMS generation 
For method development and validation, iohexol-free whole blood 
was collected from the vena mediana cubiti from healthy volunteers in K3- 
EDTA collection tubes (Vacutest® Kima, Piove di Sacco, Italy). Cali-
brator and quality control (QC) samples were prepared by adding a fixed 
volume of working solution to fresh blank whole blood. The added 
volume of working solution accounted for 4% of the total sample vol-
ume. Samples were homogenized by gently inverting the samples for 20 
times. Calibrators were prepared at eight different concentration levels, 
namely: 0.4, 1.0, 2.0, 4.0, 10, 40, 100 and 400 µg/mL. QC samples were 
prepared at the lower limit of quantification (LLOQ, 0.4 µg/mL), low 
(2.0 µg/mL), medium (20 µg/mL) and high (200 µg/mL) level. VAMS 
were prepared by dipping the outer part of the absorbent VAMS tip in 
the blood until the tip turned completely red plus an additional 2 s. 
Thereafter, VAMS were air-dried for at least 2 h. After the drying period, 
VAMS samples were either immediately analysed or in case of storage 
stability samples, stored in zip locked bags with desiccant at room 
temperature, 2–8 ◦C or − 20 ◦C. 
2.3. Sample preparation protocol for VAMS and plasma 
Sample preparation consisted of separating the VAMS tip from the 
plastic handler using a glass Pasteur pipette and transferring it into an 
Eppendorf cup. Subsequently, 25 µL of a 50 µg/mL IS solution and 175 
µL of extraction solvent was added. Five different types of extraction 
solvents were evaluated, namely 100% MeOH, 0.01% FA in MeOH/H2O 
(80/20, v/v), 5% perchloric acid in H2O (v/v), 10% TCA in H2O (w/v) 
and H2O/ACN/acetone (30/35/35, v/v/v). After thorough vortex mix-
ing for 2 min, the cups were sonicated for 30 min, followed by an in-
cubation at room temperature for 30 min. Finally, the samples were 
centrifuged for 10 min (16,200×g, 4 ◦C), whereafter the supernatant 
was transferred into an autosampler vial. A slightly modified protocol 
was used for the extraction with H2O/ACN/acetone. In this case 1 mL of 
extraction solvent was added. After sonication, incubation and centri-
fugation, the supernatant was transferred to another tube and evapo-
rated under a gentle N2 stream (40 ± 5 ◦C). Next, the dry residue was 
reconstituted in 200 µL of UP water. After vortex mixing, the sample was 
transferred into an autosampler vial. A 5 µL aliquot was injected onto the 
UHPLC column. For each type of extraction solvent, VAMS devices were 
analysed in triplicate. The final sample preparation method was selected 
based on a comparison of the peak areas of the analyte obtained from 
samples spiked at a concentration level of 100 µg/mL (n = 3) for each 
condition. In the final method, an injection volume of 1 µL was applied. 
For the determination of iohexol in plasma, blank plasma was ob-
tained from the same healthy volunteers as used for the VAMS genera-
tion. Therefore, blood was collected in K3-EDTA collection tubes and 
centrifuged at 2,095×g for 10 min. The sample preparation of the 
plasma samples was adopted from a previously in-house developed and 
validated method for the determination of iohexol in human plasma. 
Briefly, to 100 µL of plasma 12.5 µL of a 50 µg/mL IS solution and 100 µL 
of UP water were added. Subsequently, samples were vortex mixed for 
10 s followed by an equilibration period of 5 min. After addition of 15 µL 
of trifluoroacetic acid to precipitate the proteins, samples were vortex 
mixed and centrifuged for 15 min (16,200×g, 4 ◦C). The clear super-
natant was transferred into an autosampler vial. The injection volume 
was 1 µL. 
2.4. UHPLC-MS/MS method 
The plasma and VAMS samples were analysed using the same 
UHPLC-MS/MS method. Chromatographic separation was achieved on a 
Hypersil Gold aQ column (1.9 µm, 100 × 2.1 mm) protected by an 
UHPLC filter (0.2 µm, 2.1 mm ID) (ThermoFisher Scientific, Waltham, 
Massachusetts, United States). Gradient elution was established with a 
mobile phase consisting of 0.1% (v/v) FA in H2O (eluent A) and 0.1% (v/ 
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v) FA in MeOH (eluent B) at a flow rate of 0.4 mL/min. Following 
gradient program was run: 0.0–1.5 min (100% A, 0% B), 1.5–2.5 min 
(linear gradient to 60% B), 2.5–3.5 min (40% A, 60% B), 3.5–4.0 min 
(linear gradient to 100% A), 4.0–9.0 min (100% A, 0% B). Column and 
autosampler temperature were set at 30 ◦C and 10 ◦C, respectively. 
The UHPLC column effluent was interfaced to a Quattro Premier XE 
triple quadrupole mass spectrometer (Waters, Zellik, Belgium) equipped 
with an electrospray ionization (ESI) probe operating in the positive 
ionization mode. For iohexol, two precursor-to-product ion transitions 
were monitored for identification (m/z 822.0 → 731.2) and quantifica-
tion (m/z 822.0 → 804.0). For the IS, iohexol-d5, the transitions m/z 
827.0 → 736.1 and m/z 827.0 → 809.0 were used for identification and 
quantification, respectively. A collision energy of 25 eV for the quanti-
fication ions and 20 eV for the identification ions was applied. The cone 
voltage was set at 40 V. Masslynx software 4.1 (Waters Corp., Milford, 
MA, USA) was used for data acquisition and processing. 
2.5. Analytical method validation 
The VAMS method was validated by a set of parameters that were 
based on recommendations as defined by the European Medicines 
Agency (EMA) guidelines for bioanalytical method validation supple-
mented with recommendations defined in literature [32–36]. The vali-
dation encompassed an evaluation of the following parameters: 
linearity, within- and between-day accuracy and precision, lower limit 
of quantification (LLOQ), limit of detection (LOD), carry-over, selec-
tivity, extraction recovery, signal suppression and enhancement (SSE), 
short- and long-term storage stability and haematocrit (Hct) effect. 
To evaluate linearity, 8-point, matrix-matched calibration curves 
were constructed by plotting the ratio area analyte/area IS against the 
nominal concentration on three different days. Both the correlation 
coefficient (r) and goodness-of-fit coefficient (gof) were evaluated [33]. 











Values of r and gof should be higher than 0.99 and below 10%, 
respectively. To determine the weighting factor (unweighted, 1/x or 1/ 
x2), the gof coefficient of the 3 calibration curves are summed up per 
weighting factor. The weighting factor that results in the smallest sum of 
gof, is considered as most appropriate. In the selected model, the 
calculated concentrations of all included calibrator samples should 
comply with the criteria for accuracy. 
Within-day accuracy and precision were determined using six QC 
samples spiked at each concentration level and analysed on the same 
day. Between-day accuracy and precision were evaluated by analysing 
two QC samples at each concentration level on 3 different days. QC 
samples were prepared at four concentration levels: 0.4 μg/mL (LLOQ), 
2.0 μg/mL (low QC), 20 μg/mL (medium QC) and 200 μg/mL (high QC). 
Values for accuracy (%bias) must be less than ±15%, except for the 
LLOQ where a bias of ±20% is allowed. The precision is expressed by the 
relative standard deviation (RSD, %). RSD% values for within-day and 
between-day precision were considered acceptable if they were less than 
±20% at the LLOQ level and less than ±15% at other concentration 
levels. 
The LLOQ was the smallest measured analyte concentration which 
can be determined with specified degree of accuracy and precision. 
Moreover, the LLOQ was established as the lowest point of the calibra-
tion curve. The limit of detection, which is defined as the lowest con-
centration from which it is possible to deduce the presence of the analyte 
in the test sample with acceptable certainty, was determined by calcu-
lating the analyte concentration that corresponds with a S/N ratio of 3/ 
1, based on the S/N ratio of the analyte in the LLOQ samples [34]. 
The presence of carry-over was verified by injection of neat solvent 
after the highest calibration sample. If a peak was observed in the 
elution zone of the analyte or IS, the peak area must be below 20% of the 
mean peak area of the LLOQ samples for the analyte and below 5% of the 
calibrator samples for the IS. The selectivity of the method was deter-
mined by evaluating blank VAMS samples obtained from four different 
adults, who did not receive iohexol. Identical criteria were applied as for 
carry-over. 
The evaluation of SSE and extraction recovery was based on the 
approach suggested by Matuszewski et al. [37]. The SSE was investi-
gated at low and high QC level in triplicate. Therefore, VAMS generated 
with blank blood (Hct= ± 40%) were extracted by the extraction pro-
tocol (A). Thereafter, extracts were spiked at concentrations corre-
sponding to the concentration in blood, 2 and 200 µg/mL, respectively. 
Also, solvent samples, containing 10% TCA in H2O/H2O (7/1, v/v) were 
spiked at the same concentration levels (B). Absolute SSE (%) was 
calculated by dividing the peak area of A by the peak area of B, and 
multiplying it by 100. To evaluate extraction recovery, samples were 
spiked prior (C) and post (A) extraction. Extraction recovery (%) was 
determined by dividing the peak area of C by the peak area of A, 
multiplied by 100. 
Short-term and long-term stability of iohexol in VAMS were deter-
mined after storage for 48, 91 and 245 days at room temperature, 2–8 ◦C 
and − 20 ◦C. At each temperature and time point, triplicate QC samples 
were analysed at a concentration level of 2 and 200 µg/mL. The samples 
stored at − 20 ◦C for 48 days also underwent three freeze–thaw cycles. 
Additionally, stability of the VAMS samples during storage for 2 days at 
60 ◦C and stability of the processed samples in the autosampler (4 ◦C) 
were determined. The concentration of the stability samples was 
determined using a freshly prepared calibration curve. The obtained 
concentrations should be within − 15% to +15% of the concentrations 
obtained from VAMS that were prepared together with the stability 
samples, but that were immediately analysed. Also the stability during 
sample collection and drying time was established using the approach 
described by Spooner et al. [35]. Whole blood was spiked at a concen-
tration level of 2 and 200 µg/mL. The whole blood was incubated for 30 
min at 37 ◦C, to mimic the collection of a blood sample, which was 
followed by leaving the blood sample at ambient room temperature for 
2 h to mimic the drying process. The analyte to IS peak area ratio of these 
samples (3 replicates/concentration) was compared against those of the 
samples extracted immediately upon spiking. Twenty µL of whole blood 
was extracted as the VAMS samples. However, no sonication and incu-
bation at room temperature was performed. 
During the validation, donor blood with a haematocrit of around 
40% was used. Blood with a lower/higher Hct value was prepared by 
adding or removing an appropriate volume of plasma to evaluate the 
effect of Hct on the accuracy and precision of the method. To evaluate 
this Hct effect, blank blood with approximate Hct levels of 20, 50 and 
60% was prepared and spiked with iohexol. VAMS were generated and 
extracted as mentioned above. Concentrations of iohexol in these VAMS 
were determined using a calibration curve constructed with blood of 
normal Hct (±40%). Hct levels were determined by the laboratory of the 
Ghent University Hospital. 
The iohexol plasma method was validated according to the same 
guidelines as the iohexol VAMS whole blood assay. For plasma analysis, 
matrix-matched calibrators were prepared over a concentration range of 
0.5–750 µg/mL. QC samples were prepared at the lower LLOQ (0.5 µg/ 
mL), low (2.5 µg/mL), medium (25 µg/mL), high (250 µg/mL) and upper 
limit of quantification (750 µg/mL) level. Additionally, the effect of the 
used anticoagulants on the quantification of iohexol was evaluated. 
Therefore, calibration curves using lithium-heparin plasma and EDTA 
plasma were constructed. In addition, QC samples (n = 3, EDTA plasma) 
at low, medium and upper limit of quantification level were simulta-
neously analysed and quantified using the calibration curve constructed 
with heparin plasma. 
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2.6. Clinical suitability 
2.6.1. Sampling and analysis 
The applicability of this validated VAMS method was determined by 
comparing GFR values obtained by VAMS analysis with those obtained 
by conventional blood sampling and quantification of iohexol in plasma. 
Samples were collected from 20 patients admitted to the paediatric 
intensive care unit (PICU). Patients received an intravenous bolus in-
jection of iohexol (Omnipaque 300®, GE Healthcare, Eindhoven, The 
Netherlands) following a weight-based dosing. Children below 10 kg BW 
received 1 mL of iohexol solution, except neonates who received 0.5 mL. 
Two, 3 or 4 mL of Omnipaque solution was administered to children 
within the weight category of [10–19 kg], [20–29 kg], [30–39 kg], 
respectively. Above a BW of 40 kg, a maximum of 5 mL iohexol solution 
was administered. Blood collections (0.6–1 mL/collection point) were 
performed 20 min, 1 and 4 h after iohexol administration from the 
arterial or venous catheter using a syringe. These sampling points were 
selected based on previous research performed by Dhont et al. (unpub-
lished data). VAMS samples were prepared in duplicate by dipping the 
outer part of the absorbent VAMS tip in the blood at the tip of the sy-
ringe. VAMS were further handled and stored as described under section 
‘VAMS generation’. Furthermore, the remaining blood in the syringe 
was collected in lithium-heparin collection tubes. VAMS samples and 
plasma samples were stored for maximum 3 months at room tempera-
ture and − 80 ◦C, respectively. 
This study was approved by the Ethics Committee of Ghent Univer-
sity Hospital (2018/0170). Informed consent was provided by the par-
ents or their legal representative. 
During analysis, working solutions for VAMS and plasma analyses 
were prepared from the same stock solution. Furthermore, the samples 
of each individual were analysed on the same day to avoid inter-day 
differences. 
2.6.2. GFR determinations 
The GFR was determined as the total body clearance of iohexol. The 
plasma concentration–time data was analysed by non-compartmental 
modelling using Phoenix® 8.1 (Certara, USA). The GFR was calculated 




where AUC0→inf is the area under the plasma concentration-time curve 
from time zero extrapolated to infinity, CL is the total body clearance 
and Dose is the dose of iohexol administered. The GFRs were indexed to 
body surface area (BSA) according to the formula of Dubois-Dubois [38]. 
Blood iohexol concentrations, obtained by VAMS (CIOH,VAMS), were 
corrected according to patients’ haematocrit to estimate the plasma 
levels (CIOH,Pl) of iohexol using following formula: 
CIOH,Pl =
CIOH,VAMS
1 − Hct 
The latter formula is applicable since it has previously been 
demonstrated that iohexol is not distributed to red blood cells [23,39]. 
2.6.3. Statistical analysis 
The agreement and correlation of plasma concentrations and GFRs 
obtained from VAMS and the conventional plasma method were 
assessed. The Pearson’s correlation coefficient was used to evaluate the 
degree of correlation. Additionally, Passing-Bablok regression was per-
formed. Bland-Altman analysis was used to further assess the agreement. 
Accuracy of the GFR measurements was also determined by calculating 
the percentage of VAMS results within 10% (P10), 15% (P15) and 30% 
(P30) of the plasma reference method. A paired t-test was performed to 
compare plasma concentrations and GFR measurements obtained via 
VAMS and the conventional plasma method. Statistical analyses were 
performed using IBM SPSS® statistics version 26, XLSTAT version 
2020.4 and Prism version 6 (GraphPad). The level of significance was set 
at α = 0.05. Where appropriate, mean ± standard deviation (SD) are 
given. 
3. Results and discussion 
3.1. Chromatographic separation 
The LC-MS/MS-procedure was based on a method previously pub-
lished by Dhondt et al. [40]. The method was adapted in such way that 
the chromatographic run time was reduced from 10 to 9 min. This was 
accomplished by making slight adjustments to the flow rate and mobile 
phase gradient. In contrast to some other published chromatographic 
methods, it was decided not to separate the iohexol isomers, endo- and 
exo-iohexol, considering no difference in clearance between the two 
isomers is reported in humans [17,41,42]. Furthermore, when iohexol 
analytical standard is used to prepare stock solutions, the separation of 
the iohexol isomers makes the method prone to errors. More specifically, 
when dissolving iohexol powder, first an equilibrium between the two 
isomers must be reached before employing it. The time to which this 
equilibrium is reached is mainly temperature dependent and should be 
tested [43]. In the final method, the retention time of iohexol and 
iohexol-d5 was 2.71 min. Representative chromatograms are presented 
in Supplementary Fig. S1. 
3.2. VAMS extraction optimisation 
Five different extraction solvents were evaluated during this study. 
As depicted in Fig. 1, peak areas of iohexol were remarkably higher 
when extraction was performed with an aqueous solution containing 
5–10% strong acid. The use of 5% perchloric acid and 10% TCA in H2O 
yielded comparable mean peak areas. This could be both the result of a 
higher extraction recovery, signal enhancement or the presence of signal 
suppression when no acid is used during extraction. The relative stan-
dard deviation (RSD%) of the peak areas was remarkably higher for 10% 
TCA (15.57%) than for 5% perchloric acid (1.80%). This observation 
was related to one deviating sample in case of TCA. However, this did 
not seem to be the result of a lower reproducibility of the extraction, 
since the RSD% of the peak area ratio of iohexol/iohexol-d5 was even 
better for TCA (1.1%) than for perchloric acid (2.5%). Based on that 
observation, 10% TCA was selected as final extraction procedure. 
Extraction recoveries with this extraction solvent were good with mean 
Fig. 1. Mean absolute areas (±standard deviation) of iohexol obtained after 
extraction of VAMS samples spiked at 100 µg/mL with different extraction 
solvents. The injection volume was 5 µL. 
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(±SD) values of 104 (±12) and 107 (±3) %, at low and high QC level, 
respectively. These extraction recoveries are higher than those obtained 
using an Ostro-96® well plate (53.6 – 65.7%) for the extraction of 
iohexol in VAMS [31]. Furthermore, similar extraction recoveries with 
Ostro® plates were obtained for the determination of iohexol in chicken 
plasma [40]. 
3.3. Method validation 
The calibration curves were linear within a concentration range of 
0.40 and 400 µg/mL iohexol in blood. The best fit was obtained when 
applying a 1/x2 weighting. The calibration range was in the same order 
of magnitude as reported by Ion et al. (1–500 µg/mL) applying VAMS 
[31]. This calibration range comprises concentrations obtained after 
injection of the above mentioned iohexol doses to paediatric patients. 
Values of r and gof, determined on three days, ranged from 0.997 to 
0.999 and 3.70 to 7.06%, respectively. The results of the within- and 
between-day accuracy and precision evaluation are summarized in 
Table 1. At all specified levels, the predefined criteria were fulfilled. The 
LOQ was set at 0.40 µg/mL. The LOD was calculated to be 9.27 ng/mL. 
Limited carry-over was observed in the solvent sample injected after 
the highest calibrator. If a peak was observed at the retention time of 
iohexol, the area never exceeded 13.5% of the mean peak area in the 
LLOQ samples. Hence, the predefined criteria for carry-over were met. 
For the IS, no peak in the solvent samples was observed. As shown in 
Supplementary Fig. S1b, no interference peaks at the retention time of 
iohexol were observed in the blank VAMS samples. The same observa-
tions were made for iohexol-d5. Consequently, the selectivity of the 
method was demonstrated. 
Matrix-effects, which can be observed as ion suppression or 
enhancement, can dramatically affect the analytical performance of an 
LC-MS/MS method [44]. Therefore, it is mandatory to evaluate SSE 
when validating such analytical methods. In this study, the mean (±SD) 
observed absolute SSE values were 94 ± 5% and 103 ± 5% at low and 
high QC level, respectively. Hence, minimal SSE was observed. When 
corrected for the IS, the mean (±SD) relative SSE values were 102 ± 7% 
and 101 ± 2% at low and high QC level. Based on these results, the use of 
the isotopically labelled IS, iohexol-d5, seemed not mandatory to correct 
for possible SSE. Nevertheless, it has previously been observed that not 
only endogenous compounds but also exogenous components, such as 
lithium heparin, can cause ion suppression or enhancement [45]. In 
paediatric septic patients, anti-coagulants such as heparin, are 
frequently administered to prevent tissue hypo-oxygenation and to 
attenuate organ damage and dysfunction [46]. Since the clinical samples 
were obtained from ICU-admitted paediatric patients, often adminis-
tered various exogenous compounds such a heparin, the use of an 
isotopically labelled IS was preferred in order to compensate for unex-
pected matrix-effects. 
It has previously been demonstrated that analyte recovery in VAMS 
can be influenced by haematocrit [47,48]. Generally, in healthy adults 
normal haematocrit values range between 39 and 50% [49]. In children, 
Hct values are more variable, since it varies in function of age. At 2 
months of age reported Hct levels are between 26.8 and 37.6% (95% 
range) [50]. These values increase to reach adult values at an age of 
10–15 years [51]. Furthermore, Hct levels can be influenced by various 
pathologies and medical intervention. Consequently, recovery must be 
determined over a wide range of Hct levels. In this study, QC samples 
with 3 different Hct levels (21.0; 41.7; 63.9%) were initially prepared, to 
evaluate the impact of haematocrit on the accuracy and precision. These 
QC samples were quantified using a calibration curve prepared with 
blood of a normal Hct level (41.7%). As illustrated in Fig. 2, the QC 
samples with a Hct level of 21.0 and 41.7% met the predefined accep-
tance criteria for accuracy. Nevertheless, a major deviation was 
observed at a Hct of 63.9%. To exclude this was the result of insufficient 
homogenisation of the spiked blood due to high blood viscosity, analyses 
were repeated with samples of Hct levels of 50.1 and 60.2%. These 
samples were evaluated using a calibration curve with a Hct level of 
40.1%. Special attention was given to the appropriate homogenisation 
of the samples. The QC samples with a Hct of 50.1% demonstrated a 
limited bias of 1.8% and 5.2% at low and high concentration level, 
respectively. In comparison to the first measurement at Hct level ±60%, 
improved accuracy (%bias) values were obtained at second evaluation. 
With values of 5 and 13% at low and high QC level respectively, the 
predefined criterion (≤+15%) was met. Though there is an indication 
that the accuracy is somewhat lower than at the other studied Hct levels. 
Precision (%RSD) results of the samples at different Hct levels were 
within 0.9 and 6.3%, and 2.1 and 3.5% at low and high QC level, 
respectively. In conclusion, the quantification of iohexol in VAMS 
samples is guaranteed within a wide Hct-range of 21.0–60.2%. 
It is known that iohexol is very stable at room temperature, − 20 ◦C 
and − 80 ◦C in several matrices [7]. Also in this study, iohexol demon-
strated high stability. The working solutions of iohexol, stored at 2–8 ◦C, 
were considered stable over a period of minimum 254 days. The mean 
peak area of a working solution stored for 254 days deviated − 5.0% 
from the mean peak area (n = 3) of the working solution prepared from a 
fresh stock solution. Iohexol in matrix was considered stable during 
blood collection and drying on the VAMS. The stored samples (30 min at 
37 ◦C, 2 h at room temperature) deviated 2.7% and − 2.8% from the 
immediately analysed samples at low and high QC level, respectively. As 
presented in Table 2, all VAMS samples stored at room temperature, 
2–8 ◦C and − 20 ◦C showed<6% deviation after storage for up to 91 days. 
After storage during 245 days at 2–8 ◦C and − 20 ◦C a deviation of 
maximal 5.5% of the nominal values was observed. Nevertheless, after 
storage at room temperature during 245 days, a bias of approximately 
− 11% was observed at low and high QC level. This is still within the 
Table 1 
Results of within- and between-day accuracy (%bias) and precision (%RSD) for 
QC blood VAMS samples prepared at LLOQ (0.4 µg/mL), low (2.0 µg/mL), 
medium (20 µg/mL) and high (200 µg/mL) iohexol concentration level.  









LLOQ − 1.9  9.2 − 8.4  9.6 
Low − 0.1  5.1 3.5  5.1 
Medium 7.1  3.6 5.0  6.1 
High 2.4  4.2 6.2  2.2  
Fig. 2. Evaluation of the accuracy (%bias) of VAMS samples (n = 3, low and 
high QC level), constructed with blood with Hct 21.0, 41.7, 50.1, 63.9 and 
60.2%, determined using a calibration curve constructed with blood of a Hct 
value of ±40%. Mean (+SD) is presented. The evaluation of the Hct effect at Hct 
= ±60% was performed in duplicate on two different days. (1) and (2) refer to 
experiment 1 and 2, respectively. 
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predefined − 15–15% interval, however this can be a possible sign of 
degradation or a storage-induced recovery issue [52]. In the study of 
Salvador et al., iohexol DBS were stable at room temperature up to 9 
months [24]. No significant effect of 3 freeze–thaw steps on the analyte 
concentration was observed. Additionally, the samples stored for 2 days 
at 60 ◦C also demonstrated acceptable bias, with values of − 5.8% and 
− 8.0% at low and high concentration level, respectively. The high sta-
bility of iohexol makes it possible that clearance investigations can be 
performed in various medical settings. After sample collection, the 
samples can be easily shipped, without the need for dry ice, to a central 
laboratory. Stability of processed samples at autosampler temperature 
was demonstrated for up to 7 days. The autosampler stored QC samples 
deviated − 3.64% (low QC) and − 0.68% (high QC) from their concen-
tration measured immediately after preparation. 
A summary of the validation results for the plasma analysis method 
along with the acceptance criteria can be found in supplementary 
Table S1. The type of anticoagulants did not affect the quantification of 
iohexol in plasma (Fig. S2 and Table S2). 
3.4. Clinical suitability 
Twenty patients were recruited for this study. The patient charac-
teristics are presented in Table 3. In 7 patients, iohexol was administered 
a second time at 2–5 days after the first administration. In one patient 
iohexol was administered 3 times in a 9-day period. In four occasions, 
only 2 sampling points instead of the predefined 3 points were available 
for GFR determinations. Therefore, these GFR measurements were not 
included in the comparison of VAMS and the conventional plasma 
method. Eventually, 83 paired patients samples and 25 paired GFR 
measurements using both the conventional sampling technique and 
VAMS technique were obtained. With this number of samples, the 
minimal recommended amount of 20 paired samples was surpassed. The 
FDA recommends a minimum of 20 paired samples in bridging studies to 
appropriately evaluate the agreement between two different bio-
analytical methods [53]. 
An acceptable correlation (r = 0.98, p < 0.0001) was observed be-
tween plasma concentrations obtained by the conventional technique 
and calculated plasma concentrations from the VAMS samples. Passing- 
Bablok analysis (Fig. 3a) revealed no systematic error as zero is included 
in the 95% confidence interval (CI) of the intercept. A small proportional 
error was observed, since the 95% CI (0.91 to 0.97) of the slope did not 
include one. Though, Gleason et al. discussed previously that incorpo-
ration of an equivalence interval for the 95% CI could be a more 
appropriate approach in cases were very narrow CI of slopes (or in-
tercepts) are observed. As an example, it was proposed that the 95% CI 
of the slope should fall within 0.9–1.1 (10%) for the methods to be 
considered comparable [54]. The latter interval compromises the 95% 
CI of the slope observed in this study. As a consequence, the iohexol 
VAMS and conventional method can be considered comparable. The 
agreement between the two methods was demonstrated by Bland- 
Altman comparison as shown in Fig. 3b [55]. A slight negative mean 
bias of − 4.20% (95% CI − 6.58 to − 1.81%) was observed. Although 
limited, and therefore of little analytical and clinical relevance, this bias 
appeared statistically significant (p = 0.001). To which aspect(s) this 
bias is attributed is unknown. This bias could be something inherent to 
iohexol dried blood microsampling. Though an analytical source can 
also not be excluded, since a bias of − 4.20% is still within the accep-
tance criteria of accuracy when performing bioanalytical method vali-
dation. A study on a larger scale would allow the identification of the 
source of the observed bias in this study. A total of 94% of the paired 
plasma-VAMS samples were within 20% of the mean plasma concen-
tration obtained via plasma and VAMS analysis. In this way, the pre-
defined FDA acceptance criteria (67% should be ±20% of the mean) for 
incurred sample analyses are fulfilled [53]. 
As illustrated in Fig. 4a, a good correlation between the GFR esti-
mations using both techniques was observed (r = 0.99, p < 0.0001). 
Passing-Bablok analysis of the GFRs indicated good overall agreement as 
values one and zero are included in the 95% CI of the slope (0.98–1.12) 
and the intercept (− 7.18 to 3.92), respectively. Consequently, no pro-
portional or systematic errors were found in the comparison of GFR 
using both sampling methods. The agreement between GFR measure-
ments using VAMS and conventional blood sampling and quantification 
for all patients (n = 25), patients with GFR below 60 (n = 8) and above 
60 mL/min/1.73 m2 (n = 17) are presented in Table 4. Bland-Altman 
analysis for all patients demonstrated a slight mean positive bias of 
1.31% (95% CI − 4.84 to 7.47%), which was not statistically significant 
(p = 0.10). Although not significant, there seems a slight tendency of 
overestimation of the GFR by VAMS as depicted in Fig. 4b. Bland-Altman 
analysis in the >60 mL/min/1.73 m2 GFR range revealed a slight posi-
tive mean bias of 4.20% (95% CI: 0.69–7.70%). In the <60 mL/min/ 
1.73 m2 GFR range, the mean relative bias was − 4.82%, but 0 was 
included in the 95% CI (− 25.17 to 15.93%). A similar observation was 
made by Salvador et al. [24]. In the latter study, the capillary dried blood 
spot method overestimated the venous GFR to some extent in the ≥60 
mL/min/1.73 m2 GFR range. Although in the present study an accept-
able mean relative bias was observed in the lower GFR range, only 50% 
of the VAMS GFR measurements below 60 mL/min/1.73 m2 showed an 
accuracy within ±15% (P15) of the plasma GFR measurement. In 
contrast, for GFR values >60 mL/min/1.73 m2, 94% of the measure-
ments were within the ±15% interval (Table 4). In this study, primarily 
neonates demonstrated a GFR < 60 mL/min/1.73 m2. A possible solu-
tion could be the inclusion of a later time point sample. In this way small 
deviations in calculated plasma VAMS concentrations compared to the 
plasma concentrations using the conventional method will influence to a 
lesser extent the slope of the plasma concentration-time profile. 
Consequently, the slope of the plasma concentration-time profile will be 
more accurately estimated. This is of major importance, since the slope 
determines the accurate estimation of the AUC0→inf. After all, the 
AUC0→inf is included in the calculations of the iohexol clearance and 
thus GFR. Consequently, the estimation of the slope determines indi-
rectly the accurate estimation of the GFR. For patients with a severely 
reduced renal function, sampling up to 24 h after administration might 
be recommended. Previously, Ebert et al. demonstrated in older adults 
Table 2 
Stability of blood VAMS samples (n = 3) spiked at low (2 µg/mL) and high (200 
µg/mL) concentration level at different storage conditions (− 20 ◦C, 2–8 ◦C and 
room temperature (RT)). Data are presented as %bias against the concentration 
measured at time point zero (%RSD).   
%bias against concentration measured at time point zero (% 
RSD) 
QC level LOW HIGH 
Storage 
temperature 
¡20 ◦C 2–8 ◦C RT ¡20 ◦C 2–8 ◦C RT 




































* including three freeze–thaw cycles 
Table 3 
Characteristics of the patients (n = 20) obtained during the first iohexol 
administration.  
Age, years: median (range) 1.71 (0.0025–15.58) 
Gender, male: n (%) 11 (55%) 
Weight, kg: median (range) 11.5 (3.1–70) 
Height, cm: median (range) 86 (47–164) 
BSA, m2: median (range) 0.54 (0.19–1.73) 
Haematocrit, %: median (range) 30.3 (23.6–41.2) 
Serum creatinine, mg/dL: median (range) 0.47 (0.32–22.00)  
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with chronic kidney disease that measurement of iohexol clearance up to 
5 h leads to a clinically relevant overestimation of GFR compared with 
24-h measurement [56]. 
Since VAMS were generated using whole blood obtained through a 
catheter and not by conventional finger prick, the most important 
advantage of the VAMS technique in this study was undoubtedly the 
limited sampling volume. Because of this limited volume, repeated 
measurement of the GFR using iohexol is possible in the studied patients. 
Repeated measurements of the GFR are especially valuable in the criti-
cally ill paediatric patient population, since it allows detection of acute 
Fig. 3. Passing-Bablok regression analysis plotting iohexol plasma concentrations obtained using the VAMS method versus those obtained using the conventional 
sampling and plasma analysis (a). The black solid line is the slope and intercept of the regression line. The grey solid lines represent the 95% confidence interval. The 
dashed line is the identity line. Bland-Altman plot comparing plasma iohexol concentrations of blood VAMS devices and plasma (b). The % difference between the 
two methods is plotted against the average concentrations of iohexol. % difference is calculated by (plasma iohexol concentration estimated via VAMS – plasma 
iohexol concentration)/average. The mean bias is presented as a full line. The 95% lower limit of agreement (LLA) and upper limit of agreement (ULA) are presented 
by broken lines. 
Fig. 4. Passing-Bablok regression analysis plotting GFRs calculated from iohexol plasma concentrations obtained using the VAMS method versus those obtained 
using the conventional sampling and plasma analysis (a). The black solid line is the slope and intercept of the regression line. The grey solid lines represent the 95% 
confidence interval. The dashed line is the identity line. Bland-Altman plot comparing GFR values obtained using blood VAMS devices and a conventional plasma 
method (b). The % difference between the two methods is plotted against the average GFR values. % difference is calculated by (GFR estimated via VAMS – GFR 
estimated via the conventional method)/average. The mean bias is presented as a full line. The 95% lower limit of agreement (LLA) and upper limit of agreement 
(ULA) are presented by broken lines. 
Table 4 
Agreement of the GFR calculated using VAMS samples against GFR obtained using the conventional plasma method. P10, P15 and P30 represent the percentage of 
VAMS GFR measurements within 10, 15 and 30% of the GFR obtained from plasma samples. The median GFR is calculated from the GFR obtained by the VAMS 




n Mean absolute 
bias (mL/min/ 
1.73 m2) 








95% CI bias 
(%) 




















17  4.14 0.41–7.87 − 10.07–18.35  4.20 0.69–7.70 − 9.16–17.56 71 94 100 
CI = Confidence Interval, LoA = Limits of Agreement. 
L. Dhondt et al.                                                                                                                                                                                                                                  
Journal of Chromatography B 1171 (2021) 122623
8
fluctuations in renal function. Consequently, clinicians are more able to 
respond appropriately on the presence/evolution of augmented renal 
clearance or acute kidney injury. In patients without catheter, the use of 
VAMS microsampling offers, besides the limited sampling volume, some 
other advantages. First, microsamples are more easily obtained by fin-
gerprick than by conventional blood sampling (phlebotomy). Conse-
quently, microsampling dramatically improves feasibility and reduces 
cost. In addition, a fingerprick may be less intimidating for children than 
phlebotomy. Also for nonhospitalized patients, the use of microsampling 
can be favourable. More specifically, after injection of iohexol by a 
general practitioner, the patient does not need to remain in-clinic for 
several hours after administration of the marker in order to collect serial 
blood samples. Self-collection of VAMS can be performed by the patient 
(or parent) himself at predefined time points. Subsequently, the dried 
microsamples can be sent back to the laboratory for analysis. Notwith-
standing these advantages, it is important to recognize that collection of 
VAMS samples requires a high level of training, Therefore, the appli-
cation of microsampling by the patient (or parent) himself might be only 
beneficial in patients where repetitive measurements of the GFR are 
required. 
It is important to recognize that this research had limitations. First, it 
was decided to prepare the VAMS samples by dipping the outer part of 
the absorbent VAMS tip in arterial or venous blood drawn with a sy-
ringe, and not in blood obtained by a conventional fingerprick. Since 
this study was conducted in paediatric ICU patients, access via a catheter 
was always available. Hence, via this collection method no extra prick 
events were mandatory, which is preferable in this young and vulner-
able population. Consequently this study does not account for variations 
due to sampling capillary blood via finger prick. Nevertheless, previous 
studies demonstrated comparable iohexol results by finger prick and 
conventional venous blood sampling [25,26]. Secondly, our study was 
performed in a relative small and very heterogeneous population. 
Further research is necessary to confirm the suitability of the VAMS 
technology as alternative sampling strategy in a large-scale, multi-centre 
study, including all age categories, with both (supra-) normal and 
decreased renal function. Before such a large scale study can be per-
formed, the selection of optimal sampling protocols seems necessary. 
4. Conclusion 
A new, fully validated analytical method was developed for the 
quantification of iohexol in VAMS samples. This simple and cost- 
effective method fulfilled all pre-set validation acceptance criteria. 
The haematocrit effect on recovery of iohexol in VAMS was limited, 
since iohexol could be accurately quantified within a haematocrit range 
of 20–60%. Furthermore, long-term stability of iohexol in VAMS was 
demonstrated at − 20 ◦C, 2–8 ◦C and room temperature. Iohexol plasma 
concentrations, obtained by a conventional plasma collection method, 
and estimated plasma concentrations, obtained from VAMS, demon-
strated a good correlation and an acceptable bias. Hence, GFR calculated 
from VAMS and the conventional plasma method also presented good 
correlation over the tested GFR range. The agreement between the two 
methods was satisfactory for GFR values >60 mL/min/1.73 m2. 
Nevertheless, for GFR values <60 mL/min/1.73 m2 the agreement was 
lower. 
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